Answers are grounded in this paper and cite their sources.
Circulating microRNAs (miRNAs) have demonstrated potential as non-invasive biomarkers for diagnosis, prognosis, and treatment monitoring across various disorders. These small RNA molecules that don't code for anything are very stable in biofluids like blood, urine, and saliva, and they control gene expression after transcription. Their disease-specific expression traits make them good candidates for precision medicine. This study summarises the biosynthesis, release mechanisms, detection techniques, and clinical applications of circulating miRNAs in cancer, cardiovascular, neurological, and metabolic disorders. Advances in liquid biopsy technology, artificial intelligence-based data processing, and high-throughput sequencing have made them better at diagnosing diseases. But there are still problems like biological variability, a lack of standardisation, and the need for strong clinical validation.
No takes yet. Share an insight, caveat, or question.
Takate et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: